Patents Assigned to JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.
  • LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof
    Patent number: 11981733
    Abstract: Provided are a LAG-3 antibody, an antigen-binding fragment thereof, and a pharmaceutical application thereof. Further, provided are a chimeric antibody comprising a CDR of the LAG-3 antibody, a humanized antibody, a pharmaceutical composition comprising the LAG-3 antibody and the antigen-binding fragment thereof, and an application of the pharmaceutical composition as an antineoplastic drug. Particularly, provided is an application of a humanized LAG-3 antibody in preparation of drugs for treatment of diseases involving immune cells.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: May 14, 2024
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Zhuoxiao Cao, Yayuan Fu, Qiyue Hu, Weikang Tao, Lianshan Zhang, Piaoyang Sun
  • PHARMACEUTICAL COMPOSITION COMPRISING ANTI-CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY
    Publication number: 20230416352
    Abstract: Provided is a pharmaceutical composition comprising an anti-connective tissue growth factor antibody. In another aspect, further provided is a use of the pharmaceutical composition comprising an anti-connective tissue growth factor antibody.
    Type: Application
    Filed: December 3, 2021
    Publication date: December 28, 2023
    Applicants: JIANGSU HENGRUI PHARMACEUTICALS CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
    Inventors: Xiazhen MA, Tingting WU, Xun LIU
  • Pharmaceutical composition
    Patent number: 11801252
    Abstract: The present disclosure relates to a pharmaceutical composition. Specifically, a pharmaceutical composition of abiraterone acetate is provided, wherein a 300 mg dose of abiraterone acetate is bioequivalent to a 1000 mg dose of Zytiga® in healthy male subjects in a fasting state.
    Type: Grant
    Filed: March 4, 2022
    Date of Patent: October 31, 2023
    Assignee: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
    Inventors: Caiyun Pan, Ailing Chen, Kai Pan, Kai Liu, Zhirong Mo
  • PREPARATION METHOD FOR ANTIBODY MEDICAMENT CONJUGATE
    Publication number: 20230241242
    Abstract: Disclosed is a preparation method for an antibody medicament conjugate, comprising steps for synthesizing and purifying same.
    Type: Application
    Filed: March 25, 2021
    Publication date: August 3, 2023
    Applicants: JIANGSU HENGRUI PHARMACEUTICALS CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
    Inventors: Zhi LIANG, Lin WENFANG, Ruijun SHI, Xun LIU
  • PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF
    Publication number: 20230165969
    Abstract: A pharmaceutical composition, comprising an antibody drug conjugate in a buffer solution. The antibody drug conjugate has a structure represented by the general formula (Pc-L-Y-D). The pharmaceutical composition further comprises sugar and a surfactant.
    Type: Application
    Filed: March 25, 2021
    Publication date: June 1, 2023
    Applicants: JIANGSU HENGRUI PHARMACEUTICALS CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
    Inventors: Zhanlong YUE, Zhen YAN, Xun LIU
  • ANTI-PSMA ANTIBODY-EXATECAN ANALOGUE CONJUGATE AND MEDICAL USE THEREOF
    Publication number: 20230140397
    Abstract: Provided are an anti-PSMA antibody-Exatecan analogue conjugate and medical use thereof. Specifically, provided is an anti-PSMA antibody-drug conjugate represented by general formula (Pc-L-Y-D), wherein Pc is an anti-PSMA antibody or an antigen-binding fragment thereof.
    Type: Application
    Filed: March 25, 2021
    Publication date: May 4, 2023
    Applicants: JIANGSU HENGRUI PHARMACEUTICALS CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
    Inventors: Hua YING, Xiaomin ZHANG, Xiaoying YANG, Weikang TAO